Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb;20(2):116-132.
doi: 10.1038/s41584-023-01065-6. Epub 2024 Jan 11.

Recent advances and evolving concepts in Still's disease

Piero Ruscitti  1 , Luca Cantarini  2 , Peter A Nigrovic  3   4 , Dennis McGonagle  5   6 , Roberto Giacomelli  7   8
Affiliations
Review

Recent advances and evolving concepts in Still's disease

Piero Ruscitti et al. Nat Rev Rheumatol. 2024 Feb.

Abstract

Still's disease is a rare inflammatory syndrome that encompasses systemic juvenile idiopathic arthritis and adult-onset Still's disease, both of which can exhibit life-threatening complications, including macrophage activation syndrome (MAS), a secondary form of haemophagocytic lymphohistiocytosis. Genetic insights into Still's disease involve both HLA and non-HLA susceptibility genes, suggesting the involvement of adaptive immune cell-mediated immunity. At the same time, phenotypic evidence indicates the involvement of autoinflammatory processes. Evidence also implicates the type I interferon signature, mechanistic target of rapamycin complex 1 signalling and ferritin in the pathogenesis of Still's disease and MAS. Pathological entities associated with Still's disease include lung disease that could be associated with biologic DMARDs and with the occurrence of MAS. Historically, monophasic, recurrent and persistent Still's disease courses were recognized. Newer proposals of alternative Still's disease clusters could enable better dissection of clinical heterogeneity on the basis of immune cell profiles that could represent diverse endotypes or phases of disease activity. Therapeutically, data on IL-1 and IL-6 antagonism and Janus kinase inhibition suggest the importance of early administration in Still's disease. Furthermore, there is evidence that patients who develop MAS can be treated with IFNγ antagonism. Despite these developments, unmet needs remain that can form the basis for the design of future studies leading to improvement of disease management.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Lee, J. J. Y. & Schneider, R. Systemic juvenile idiopathic arthritis. Pediatr. Clin. North. Am. 65, 691–709 (2018). - PubMed - DOI
    1. Giacomelli, R., Ruscitti, P. & Shoenfeld, Y. A comprehensive review on adult onset Still’s disease. J. Autoimmun. 93, 24–36 (2018). - PubMed - DOI
    1. Nigrovic, P. A. Autoinflammation and autoimmunity in systemic juvenile idiopathic arthritis. Proc. Natl Acad. Sci. USA 112, 15785–15786 (2015). - PubMed - PMC - DOI
    1. Gerfaud-Valentin, M., Jamilloux, Y., Iwaz, J. & Sève, P. Adult-onset Still’s disease. Autoimmun. Rev. 13, 708–722 (2014). - PubMed - DOI
    1. Ombrello, M. J. et al. HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proc. Natl Acad. Sci. USA 112, 15970–15975 (2015). - PubMed - PMC - DOI

MeSH terms

Substances

LinkOut - more resources